Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Per Ljungman, Rafael de la Cámara, Małgorzata Mikulska, et al.
Leukemia (2021) Vol. 35, Iss. 10, pp. 2885-2894
Open Access | Times Cited: 207

Showing 1-25 of 207 citing articles:

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 262
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
Rabah Redjoul, Anne Le Bouter, Florence Beckerich, et al.
The Lancet (2021) Vol. 398, Iss. 10297, pp. 298-299
Open Access | Times Cited: 116
COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 108
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 105
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1760-1774
Open Access | Times Cited: 80
International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update
Seth J. Rotz, Neel S. Bhatt, Betty K. Hamilton, et al.
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 4, pp. 349-385
Open Access | Times Cited: 19
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne M. Spanjaart, Per Ljungman, Rafael de la Cámara, et al.
Leukemia (2021) Vol. 35, Iss. 12, pp. 3585-3588
Open Access | Times Cited: 98
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood (2021) Vol. 139, Iss. 10, pp. 1588-1592
Open Access | Times Cited: 82
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
Rabah Redjoul, Anne Le Bouter, Vincent Parinet, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 10, pp. e681-e683
Open Access | Times Cited: 74
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients
Alexis Maillard, Rabah Redjoul, Marion Klemencie, et al.
Blood (2021) Vol. 139, Iss. 1, pp. 134-137
Open Access | Times Cited: 67
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Nico Gagelmann, Francesco Passamonti, Christine Wolschke, et al.
Haematologica (2021) Vol. 107, Iss. 8, pp. 1840-1849
Open Access | Times Cited: 65
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Alessandro Busca, Jon Salmanton‐García, Paolo Corradini, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2427-2433
Open Access | Times Cited: 64
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group
José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, et al.
American Journal of Hematology (2021) Vol. 97, Iss. 1, pp. 30-42
Open Access | Times Cited: 61
Humoral and Cellular Vaccination Responses against SARS-CoV-2 in Hematopoietic Stem Cell Transplant Recipients
Monika Lindemann, Vesna Klisanin, Laura Thümmler, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1075-1075
Open Access | Times Cited: 60
Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis
Moazzam Shahzad, Sibgha Gull Chaudhary, Muhammad Usman Zafar, et al.
Transplant Infectious Disease (2022) Vol. 24, Iss. 2
Closed Access | Times Cited: 39
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients
Xi Wu, Lu Wang, Lu Shen, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 37
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
Federico Baldi, Chiara Dentone, Małgorzata Mikulska, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 29
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Alessandro Busca, Jon Salmanton‐García, Francesco Marchesi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 28
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination
José Luís Piñana, Rodrigo Martino, Lourdes Vázquez, et al.
Bone Marrow Transplantation (2023) Vol. 58, Iss. 5, pp. 567-580
Open Access | Times Cited: 24
Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes
Achilleas Livieratos, Charalambos Gogos, Karolina Akinosoglou
Viruses (2024) Vol. 16, Iss. 5, pp. 685-685
Open Access | Times Cited: 9
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Francesco Marchesi, Jon Salmanton‐García, Ziad Emarah, et al.
Haematologica (2022) Vol. 108, Iss. 1, pp. 22-33
Open Access | Times Cited: 34
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 33
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
Firas El Chaer, Jeffery J. Auletta, Roy F. Chemaly
Blood (2022) Vol. 140, Iss. 7, pp. 673-684
Open Access | Times Cited: 28
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101983-101983
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top